Cancer Communications (Jan 2024)
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
- Feng‐Hua Wang,
- Xiao‐Tian Zhang,
- Lei Tang,
- Qi Wu,
- Mu‐Yan Cai,
- Yuan‐Fang Li,
- Xiu‐Juan Qu,
- Hong Qiu,
- Yu‐Jing Zhang,
- Jie‐Er Ying,
- Jun Zhang,
- Ling‐Yu Sun,
- Rong‐Bo Lin,
- Chang Wang,
- Hao Liu,
- Miao‐Zhen Qiu,
- Wen‐Long Guan,
- Sheng‐Xiang Rao,
- Jia‐Fu Ji,
- Yan Xin,
- Wei‐Qi Sheng,
- Hui‐Mian Xu,
- Zhi‐Wei Zhou,
- Ai‐Ping Zhou,
- Jing Jin,
- Xiang‐Lin Yuan,
- Feng Bi,
- Tian‐Shu Liu,
- Han Liang,
- Yan‐Qiao Zhang,
- Guo‐Xin Li,
- Jun Liang,
- Bao‐Rui Liu,
- Lin Shen,
- Jin Li,
- Rui‐Hua Xu
Affiliations
- Feng‐Hua Wang
- Department of Medical Oncology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
- Xiao‐Tian Zhang
- Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Peking University Cancer Hospital Beijing P. R. China
- Lei Tang
- Department of Radiology Peking University Cancer Hospital Beijing P. R. China
- Qi Wu
- Department of Endoscopy Center Peking University Cancer Hospital Beijing P. R. China
- Mu‐Yan Cai
- Department of Pathology Sun Yat‐sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong P. R. China
- Yuan‐Fang Li
- Department of Gastric Surgery Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
- Xiu‐Juan Qu
- Department of Medical Oncology The First Hospital of China Medical University Shenyang Liaoning P. R. China
- Hong Qiu
- Department of Medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei P. R. China
- Yu‐Jing Zhang
- Department of Radiotherapy Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
- Jie‐Er Ying
- Department of Medical Oncology Zhejiang Cancer Hospital Hangzhou Zhejiang P. R. China
- Jun Zhang
- Department of Medical Oncology Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai P. R. China
- Ling‐Yu Sun
- Department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical University Harbin Heilongjiang P. R. China
- Rong‐Bo Lin
- Department of Medical Oncology Fujian Cancer Hospital Fuzhou Fujian P. R. China
- Chang Wang
- Tumor Center The First Hospital of Jilin University Changchun Jilin P. R. China
- Hao Liu
- Department of General Surgery Nanfang Hospital Southern Medical University Guangzhou Guangdong P. R. China
- Miao‐Zhen Qiu
- Department of Medical Oncology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
- Wen‐Long Guan
- Department of Medical Oncology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
- Sheng‐Xiang Rao
- Department of Radiology Zhongshan Hospital Fudan University Shanghai P. R. China
- Jia‐Fu Ji
- Department of Gastrointestinal Surgery Peking University Cancer Hospital Beijing P. R. China
- Yan Xin
- Pathology Laboratory of Gastrointestinal Tumor The First Hospital of China Medical University Shenyang Liaoning P. R. China
- Wei‐Qi Sheng
- Department of Pathology Zhongshan Hospital Affiliated to Shanghai Fudan University Shanghai P. R. China
- Hui‐Mian Xu
- Department of Gastrointestinal Oncology Surgery. The First Hospital of China Medical University Shenyang Liaoning P. R. China
- Zhi‐Wei Zhou
- Department of Gastric Surgery Sun Yat‐sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong P. R. China
- Ai‐Ping Zhou
- Department of Oncology National Cancer Center National Clinical Research Center for Cancer Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing P. R. China
- Jing Jin
- Department of Radiation Oncology Shenzhen hospital Cancer Hospital of Chinese Academy of Medical Sciences Beijing P. R. China
- Xiang‐Lin Yuan
- Department of Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei P. R. China
- Feng Bi
- Department of Abdominal Oncology West China Hospital of Sichuan University Chengdu Sichuan P. R. China
- Tian‐Shu Liu
- Department of Medical Oncology Zhongshan Hospital Affiliated to Fudan University Shanghai P. R. China
- Han Liang
- Department of Gastric Surgery Tianjin Medical University Cancer Institute & Hospital Tianjin P. R. China
- Yan‐Qiao Zhang
- Department of Medical Oncology Cancer Hospital of Harbin Medical University Harbin Heilongjiang P. R. China
- Guo‐Xin Li
- Department of General Surgery Nanfang Hospital Southern Medical University Guangzhou Guangdong P. R. China
- Jun Liang
- Department of Medical Oncology Peking University International Hospital Beijing P. R. China
- Bao‐Rui Liu
- Department of Medical Oncology Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing P. R. China
- Lin Shen
- Department of GI Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Peking University Cancer Hospital Beijing P. R. China
- Jin Li
- Department of Oncology Easter Hospital affiliated to Shanghai Tongji University Shanghai P. R. China
- Rui‐Hua Xu
- Department of Medical Oncology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
- DOI
- https://doi.org/10.1002/cac2.12516
- Journal volume & issue
-
Vol. 44,
no. 1
pp. 127 – 172
Abstract
Abstract The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence‐based medicine, healthcare resource availability, and precision medicine. These updates address the differences in epidemiological characteristics, clinicopathological features, tumor biology, treatment patterns, and drug selections between Eastern and Western gastric cancer patients. Key revisions include a structured template for imaging diagnosis reports, updated standards for molecular marker testing in pathological diagnosis, and an elevated recommendation for neoadjuvant chemotherapy in stage III gastric cancer. For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti‐angiogenic therapy and targeted drugs, along with updated management strategies for human epidermal growth factor receptor 2 (HER2)‐positive and deficient DNA mismatch repair (dMMR)/microsatellite instability‐high (MSI‐H) patients. Additionally, the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer. The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice, particularly in the heterogeneous healthcare landscape of China, while maintaining a commitment to scientific rigor, impartiality, and timely revisions.
Keywords
